Please login to the form below

Not currently logged in
Email:
Password:

Positive opinion for Zevalin

Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use gave a positive opinion for its drug Zevalin
Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for its drug Zevalin.

Pending a favourable review from the European Commission, Zevalin could receive marketing authorisation for all EU member states later this year.

Zevalin (ibritumomab tiuxetan) has been developed as a consolidation therapy for patients with follicular lymphoma, one of the most common types of non-Hodgkin's lymphoma, the fifth most prevalent form of cancer.

Dr Gunnar Riemann, member of the board of management for Bayer, said: "The CHMP's recommendation represents an important milestone for Zevalin."

"This therapy option will provide clinicians with a treatment regimen that truly could help many of their patients to an extended progression-free survival," he added.

25th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics